Director James N. Wilson filed a Form 4 with the SEC on August 18, 2026, disclosing the sale of 10,000 shares of Corcept Therapeutics common stock on August 14, 2026, executed under a pre-established 10b5-1 trading plan.

Key Highlights

  • Total shares sold: 10,000 shares of common stock (3,053 + 4,668 + 2,279) disposed of on August 14, 2026.
  • Sale prices: Three tranches sold at weighted average prices of $110.4949, $111.4425, and $112.6398 per share, respectively.
  • 10b5-1 plan: All sales were made pursuant to a 10b5-1 plan adopted by Wilson on March 12, 2026.
  • Remaining indirect ownership: Following the sales, Wilson holds 1,074,543 shares indirectly through the James N. Wilson and Pamela D. Wilson Trust.
  • Additional indirect holdings: 200,000 shares held indirectly via the James N. Wilson 2025 Grantor Retained Annuity Trust and 200,000 shares via the Pamela D. Wilson 2025 Grantor Retained Annuity Trust are also reported.
  • Ownership disclaimer: Wilson disclaims beneficial ownership of trust shares except to the extent of his pecuniary interest, according to the filing.

Wilson's Share Sales and Beneficial Ownership at Corcept Therapeutics

According to the filing, James N. Wilson, a director of Corcept Therapeutics Inc (NASDAQ:CORT), sold a combined 10,000 shares of common stock on August 14, 2026, through three separate transactions. The first tranche consisted of 3,053 shares sold at a weighted average price of $110.4949, with actual prices ranging from $110.00 to $110.98 per share. The second tranche of 4,668 shares was sold at a weighted average of $111.4425, with prices ranging from $111.01 to $112.00 per share. The third tranche of 2,279 shares was sold at a weighted average of $112.6398, with prices ranging from $112.51 to $112.83 per share.

The filing states that all three transactions were made pursuant to a Rule 10b5-1 plan that Wilson adopted on March 12, 2026. All shares were disposed of indirectly through the James N. Wilson and Pamela D. Wilson Trust. Following the reported transactions, Wilson's indirect beneficial ownership in that trust stood at 1,074,543 shares, the filing disclosed.

In addition to the trust holdings described above, the filing reports that Wilson indirectly holds 200,000 shares through the James N. Wilson 2025 Grantor Retained Annuity Trust and 200,000 shares through the Pamela D. Wilson 2025 Grantor Retained Annuity Trust. The filing notes that Wilson "has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein." No direct share ownership by Wilson was reported in this filing. The form was signed by Joseph Douglas Lyon as attorney-in-fact for Wilson.

What Was Disclosed

The filing reported the sale of 10,000 Corcept Therapeutics common shares by director James N. Wilson on August 14, 2026, via a pre-established 10b5-1 plan, along with Wilson's remaining indirect beneficial ownership across three trust vehicles.